|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Bedside index for severity in acute pancreatitis:comparison with other scoring systems in predicting severity and organ failure显示文摘BACKGROUND:The early identification of severe acute pancreatitis is important for the management and for improving outcomes.The bedside index for severity in acute pancreatitis(BISAP)has been considered as an accurate method for risk stratification in patients with acute pancreatitis.This study aimed to evaluate the comparative usefulness of the BISAP.METHODS:We retrospectively analyzed 303 patients with acute pancreatitis diagnosed at our hospital from March 2007to December 2010.BISAP,APACHE-II,Ranson criteria,and CT severity index(CTSI)of all patients were calculated.We stratified the number of patiants with severe pancreatitis,pancreatic necrosis,and organ failure as well as the number of deaths by BISAP score.We used the area under the receiveroperating curve(AUC)to compare BISAP with other scoring systems,C-reactive protein(CRP),hematocrit,and body mass index(BMI)with regard to prediction of severe acute pancreatitis,necrosis,organ failure,and death.RESULTS:Of the 303 patiants,31(10.2%)were classified as having severe acute pancreatitis.Organ failure occurred in 23(7.6%)patients,pancreatic necrosis in 40(13.2%),and death in6(2.0%).A BISAP score of 2 was a statistically significant cutoff value for the diagnosis of severe acute pancreatitis,organ failure,and mortality.AUCs for BISAP predicting severe pancreatitis and death were 0.80 and 0.86,respectively,which were similar to those for APACHE-II(0.80,0.87)and Ranson criteria(0.74,0.74)and greater than AUCs for CTSI(0.67,0.42).The AUC for organ failure predicted by BISAP,APACHE-II,Ranson criteria,and CTSI was 0.93,0.95,0.84 and 0.57,respectively.AUCs for BISAP predicting severity,organ failure,and death were greater than those for CRP(0.69,0.80,0.72),hematocrit(0.45,0.35,0.14),and BMI(0.41,0.47,0.17).CONCLUSION:The BISAP predicts severity,death,and especially organ failure in acute pancreatitis as well as APACHE-II does and better than Ranson criteria,CTSI,CRP,hematocrit,and BMI. | Ji Young Park Tae Joo Jeon Tae Hwan Ha Jin Tae Hwang Dong Hyun Sinn Tae-Hoon Oh Won Chang Shin Won-Choong | 2013 | Hepatobiliary & Pancreatic Diseases International2013，12，6： | 33 |
| 2 | Tenofovir rescue therapy for chronic hepatitis B patients after multiple treatment failures显示文摘AIM:To evaluate the efficacy and safety of tenofovir disoproxil fumarate(TDF) for chronic hepatitis B(CHB) patients after multiple failures.METHODS:A total of 29 CHB patients who had a suboptimal response or developed resistance to two or more previous nucleoside/nucleotide analogue(NA) treatments were included.Study subjects were treated with TDF alone(n = 13) or in combination with lamivudine(LAM,n = 12) or entecavir(ETV,n = 4) for ≥ 6 mo.Complete virologic response(CVR) was defined as an achievement of serum hepatitis B virus(HBV) DNA level ≤ 60 IU/mL by real-time polymerase chain reaction method during treatment.Safety assessment was based on serum creatinine and phosphorus level.Eleven patients had histories of LAM and adefovir dipivoxil(ADV) treatment and 18 patients were exposed to LAM,ADV,and ETV.Twenty-seven patients(93.1%) were hepatitis B e antigen(HBeAg) positive and the mean value of the baseline serum HBV DNA level was 5.5 log IU/mL ± 1.7 log IU/mL.The median treatment duration was 16 mo(range 7 to 29 mo).RESULTS:All the patients had been treated with LAM and developed genotypic and phenotypic resistance to it.Resistance to ADV was present in 7 patients and 10 subjects had a resistance to ETV.One patient had a resistance to both ADV and ETV.The cumulative probabilities of CVR at 12 and 24 mo of TDF containing treatment regimen calculated by the Kaplan Meier method were 86.2% and 96.6%,respectively.Although one patient failed to achieve CVR,serum HBV DNA level decreased by 3.9 log IU/mL from the baseline and the last serum HBV DNA level during treatment was 85 IU/mL,achieving near CVR.No patients in this study showed viral breakthrough or primary non-response during the follow-up period.The cumulative probability of HBeAg clearance in the 27 HBeAg positive patients was 7.4%,12%,and 27% at 6,12,and 18 mo of treatment,respectively.Treatment efficacy of TDF containing regimen was not statistically different according to the presence of specific HBV mutations.History of prior exposure to specific antiviral agents did not make a difference to treatment outcome.Treatment efficacy of TDF was not affected by combination therapy with LAM or ETV.No patient developed renal toxicity and no cases of hypophosphatemia associated with TDF therapy were observed.There were no other adverse events related to TDF therapy observed in the study subjects.CONCLUSION:TDF can be an effective and safe rescue therapy in CHB patients after multiple NA therapy failures. | Yu Jin Kim Dong Hyun Sinn Geum-Youn Gwak Moon Seok Choi Kwang Cheol Koh Seung Woon Paik Byung Chul Yoo Joon Hyeok Lee | 2012 | World Journal of Gastroenterology2012，18，47： | 16 |
| 3 | Primary prevention and treatment of venous thromboembolic events in patients with gastrointestinal cancers- Review显示文摘Venous thromboembolism event(VTE) is a common and morbid complication in cancer patients. Patients with gastrointestinal cancers often suffer from symptomatic or incidental splanchnic vein thrombosis, impaired liver function and/or thrombocytopenia. These characteristics require a thorough risk/benefit evaluation for individual patients. Considering the risk factors for the development of VTE and bleeding events in addition to recent study results may be helpful for correct initiation of primary pharmacological prevention and treatment of cancer-associated thrombosis(CAT), preferably with low molecular weight heparins(LMWH). Whereas thromboprophylaxis is most often recommended in hospitalized surgical and non-surgical patients with malignancy, there is less agreement as to its duration. With regard to ambulatory cancer patients, the lack of robust data results in low grade recommendations against routine use of anticoagulant drugs. Anticoagulation with LMWH for the first months is the evidence-based treatment for acute CAT, but duration of secondary prevention and the drug of choice are unclear. Based on published guidelines and literature, this review will focus on prevention and treatment strategies of VTE in patients with gastrointestinal cancers. | Hanno Riess Piet Habbel Anja Jühling Marianne Sinn Uwe Pelzer | 2016 | World Journal of Gastrointestinal Oncology2016，8，3： | 9 |
| 4 | Assessment of scoring systems for acute-on-chronic liver failure at predicting short-term mortality in patients with alcoholic hepatitis显示文摘AIM To assess the performance of proposed scores specific for acute-on-chronic liver failure in predicting shortterm mortality among patients with alcoholic hepatitis.METHODS We retrospectively collected data from 264 patients with clinically diagnosed alcoholic hepatitis from January to December 2013 at 21 academic hospitals in Korea. The performance for predicting short-term mortality was calculated for Chronic Liver FailureSequential Organ Failure Assessment(CLIF-SOFA), CLIF Consortium Organ Failure score(CLIF-C OFs), Maddrey'sdiscriminant function(DF), age, bilirubin, international normalized ratio and creatinine score(ABIC), Glasgow Alcoholic Hepatitis Score(GAHS), model for end-stage liver disease(MELD), and MELD-Na.RESULTS Of 264 patients, 32(12%) patients died within 28 d. The area under receiver operating characteristic curve of CLIF-SOFA, CLIF-C OFs, DF, ABIC, GAHS, MELD, and MELD-Na was 0.86(0.81-0.90), 0.89(0.84-0.92), 0.79(0.74-0.84), 0.78(0.72-0.83), 0.81(0.76-0.86), 0.83(0.78-0.88), and 0.83(0.78-0.88), respectively, for 28-d mortality. The performance of CLIF-SOFA had no statistically significant differences for 28-d mortality. The performance of CLIF-C OFs was superior to that of DF, ABIC, and GAHS, while comparable to that of MELD and MELD-Na in predicting 28-d mortality. A CLIF-SOFA score of 8 had 78.1% sensitivity and 79.7% specificity, and CLIF-C OFs of 10 had 68.8% sensitivity and 91.4% specificity for predicting 28-d mortality.CONCLUSION CLIF-SOFA and CLIF-C OF scores performed well, with comparable predictive ability for short-term mortality compared to the commonly used scoring systems in patients with alcoholic hepatitis. | Hee Yeon Kim Chang Wook Kim Tae Yeob Kim Do Seon Song Dong Hyun Sinn Eileen L Yoon Young Kul Jung Ki Tae Suk Sang Soo Lee Chang Hyeong Lee Tae Hun Kim Jeong Han Kim Hyung Joon Yim Sung Eun Kim Soon Koo Baik Byung Seok Lee Jae Young Jang Young Seok Kim Sang Gyune Kim Jin Mo Yang Joo Hyun Sohn Heon Ju Lee Seung Ha Park Eun Hee Choi Dong Joon Kim Korean Acute-on-Chronic Liver Failure Study Group | 2016 | World Journal of Gastroenterology2016，22，41： | 5 |
| 5 | Virological response to adefovir monotherapy and the risk of adefovir resistance显示文摘AIM:To evaluate virological response to adefovir(ADV) monotherapy and emergence of ADV-resistant mutations in lamivudine(LAM)-resistant chronic hepatitis B patients.METHODS:Seventy-seven patients with documented LAM resistance who were treated with 10 mg/d ADV for>96 wk were analyzed for ADV resistance.RESULTS:At week 48 and 96,eight(10%)and 14(18%)of 77 LAM-resistant patients developed the ADV-resistant strain(rtA181V/T and/or rtN236T mutations),respectively.Hepatitis B virus(HBV)DNA levels during therapy were significantly higher in patients who developed ADV resistance than in those who did not.Incidence of ADV resistance at week 96 was 11%,8%and 6%among patients with complete virological response(HBV DNA level<60 IU/mL);0%,5%and 19%among patients with partial virological response(HBV DNA level≥60 to 2000 IU/mL);and 32%,34% and 33%among patients with inadequate virological response(HBV DNA levels>2000 IU/mL)at week 12,week 24 and week 48,respectively.HBV DNA levels >2000 IU/mL at week 24 showed best performance characteristics in predicting ADV resistance.CONCLUSION:Development of ADV resistance mutations was associated with HBV DNA levels,which could identify patients with LAM resistance who are likely to respond to ADV monotherapy. | Dong Hyun Sinn Geum-Youn Gwak Moon Seok Choi Kwang Cheol Koh Seung Woon Paik Byung Chul Yoo Joon Hyeok Lee Hyang Ie Lee | 2011 | World Journal of Gastroenterology2011，17，30： | 5 |
| 6 | Appropriate empirical antibiotic use and 30-d mortality in cirrhotic patients with bacteremia显示文摘AIM: To analyze whether prompt and appropriate empirical antibiotic(AEA) use is associated with mortality in cirrhotic patients with bacteremia. METHODS: A total of 102 episodes of bacteremia in 72 patients with cirrhosis were analyzed. AEA was defined as a using or starting an antibiotic appropriate to the isolated pathogen at the time of bacteremia. The primary endpoint was 30-d mortality. RESULTS: The mortality rate at 30 d was 30.4%(31/102 episodes). Use of AEA was associated with better survival at 30 d(76.5% vs 46.9%, P = 0.05), and inappropriate empirical antibiotic(IEA) use was an independent factor associated with increased mortality(OR = 3.24; 95%CI: 1.50-7.00; P = 0.003, adjusted for age, sex, ChildPugh Class, gastrointestinal bleeding, presence of septic shock). IEA use was more frequent when the isolated pathogen was a multiresistant pathogen, and when infection was healthcare-related or hospital-acquired. CONCLUSION: AEA use was associated with increased survival of cirrhotic patients who developed bacteremia. Strategies for AEA use, tailored according to the local epidemiological patterns, are needed to improve survival of cirrhotic patients with bacteremia. | Hyun Park Ki Jun Jang Won Jang Sang Hoon Park Ji Young Park Tae Joo Jeon Tae Hoon Oh Won Chang Shin Won-Choong Choi Dong Hyun Sinn | 2015 | World Journal of Gastroenterology2015，21，12： | 4 |
| 7 | Ethnic variations in ulcerative colitis: Experience of an international hospital in Thailand显示文摘AIM: To investigate the clinical characteristics, treatment, medication use, and treatment response in patients with ulcerative colitis(UC) across ethnic groups.METHODS: This study retrospectively analyzed medical records of all 268465 patients who visited the Bumrungrad International Digestive Disease Center during 2005-2010. The demographics, clinical characteristics, medication use, results of investigations, and medical and surgical management for patients with UC were evaluated. Evaluation included sigmoidoscopy and colonoscopy performed in compliance with the American Society of Gastrointestinal Endoscopy practice guidelines. Patient ethnicities were categorized into seven groups: Thai, Oriental, South Asian(SA), Middle Eastern(ME), Caucasian, African, and Hispanic. UC pathological severity was classified into inactive, mild, moderate, and severe. Associations between categorical variables were analyzed using the χ2 or Fischer's exact test. Associations between categorical and interval variables were analyzed usingStudent's t-test and/or analysis of covariance.RESULTS: UC was diagnosed in 371 of the 268465 patients: male 56.33%; ME 42%, Caucasian 23%, and Thai 19%. Annual incidence of UC was 82 cases per 100000 with wide ethnic variation, ranging from 29 to 206 cases per 100000 in Oriental and ME patients, respectively. Of the patients with UC, 16.71% had severe UC with highest incidence among the patients from ME(20.39%) and lowest among the Caucasian population(11.90%). ME had highest proportion of pancolitis(52.90%), followed by Caucasian(45.35%) and Asian(34.40%). Only 20.93% of Caucasian patients received steroid, compared with 26.40% and 27.10% of Asian and Middle Eastern, respectively(P = 0.732). Overall, 13.72% of UC patients did not respond to steroid therapy, with non-significantly higher proportions of non-responders among Asian and Middle Eastern patients(15.22% and 15.04%, respectively)(P = 0.781). On average, 5.93% underwent surgical management with ethnic variation, ranging from 0% in African to 18% in SA. Cancer was found in three(Thai, ME, and African) cases(0.82 institution-specific incidence).CONCLUSION: Incidence, symptom duration, pathological severity, clinical manifestations, medication use, treatment response, need for surgical consultation, and cancer incidence of patients with UC potentially vary by ethnicity. | Vibhakorn Permpoon Krit Pongpirul Sinn Anuras | 2016 | World Journal of Gastrointestinal Pharmacology and Therapeutics2016，7，3： | 4 |
| 8 | 慢性乙型肝炎患者使用他汀类药物与肝细胞癌发生风险的关系显示文摘【据《Hepatology》2019年10月报道】题:慢性乙型肝炎患者使用他汀类药物与肝细胞癌发生风险的关系(作者Goh MJ等)他汀类药物具有多效性,包括化学预防作用。一些观察性研究表明他汀类药物可以预防肝细胞癌(HCC),但其在慢性乙型肝炎中与HCC的关系尚未得到充分研究。该研究旨在探索慢性乙型肝炎患者使用他汀类药物与HCC发生风险的关系。来自韩国首尔的Goh等进行了一项基于医院的回顾性队列研究,作者于2008年1月-2012年12月在韩国首尔单中心收集了7713例慢性乙型肝炎患者,主要研究结局为发生HCC。他汀类药物的使用依据世界卫生组织推荐的每日用药剂量(DDD),随访期间使用的任意种类的他汀类药物的累计每日用药剂量定义为cDDD。随访期间使用他汀类药物cDDD至少28次的患者,被定义为他汀类药物使用者(n=713),为探索他汀类药物的剂量效应关系,将他汀类药物使用剂量分成5组,分别为<28、28~365、366~730、731~1095、>1095。应用时间相关协变量的多变量Cox回归模型来分析使用他汀类药物与HCC发病率的关系。 | 周胜云 段志辉 GOH MJ SINN DH KIM S | 2020 | 临床肝胆病杂志2020，36，1： | 4 |
| 9 | Perioperative treatment options in resectable pancreatic cancer-how to improve long-term survival显示文摘Surgery remains the only chance of cure for pancreatic cancer, but only 15%-25% of patients present with resectable disease at the time of primary diagnosis. Important goals in clinical research must therefore be to allow early detection with suitable diagnostic procedures, to further broaden operation techniques and to determine the most effective perioperative treatment of either chemotherapy and/or radiation therapy. More extensive operations involving extended pancreatectomy, portal vein resection and pancreatic resection in resectable pancreatic cancer with limited liver metastasis, performed in specialized centers seem to be the surgical procedures with a possible impact on survival. After many years of stagnation in pharmacological clinical research on advanced pancreatic ductal adenocarcinomas(PDAC)- since the approval of gemcitabine in 1997- more effective cytotoxic substances(nab-paclitaxel) and combinations(FOLFIRINOX) are now available for perioperative treatment. Additionally, therapies with a broader mechanism of action are emerging(stroma depletion, immunotherapy, antiinflammation), raising hopes for more effective adjuvant and neoadjuvant treatment concepts, especially in the context of 'borderline resectability'. Only multidisciplinary approaches including radiology, surgery, medical and radiation oncology as the backbones of the treatment of potentially resectable PDAC may be able to further improve the rate of cure in the future. | Marianne Sinn Marcus Bahra Timm Denecke Sue Travis Uwe Pelzer Hanno Riess | 2016 | World Journal of Gastrointestinal Oncology2016，8，3： | 3 |
| 10 | Pre-S Mutation Is a Significant Risk Factor for Hepatocellular Carcinoma Development: A Long-Term Retrospective Cohort Study显示文摘 | Dong Hyun Sinn Moon Seok Choi Geum-Youn Gwak Yong-Han Paik Joon Hyeok Lee Kwang Cheol Koh Seung Woon Paik Byung Chul Yoo | 2013 | Digestive Diseases and Sciences2013，，3： | 2 |
| 11 | Source and optics considerations for new generation high-resolution inelastic X-ray spectrometers显示文摘 | ERCAN A E SINN H ALATAS A | 2001 | Nuclear Instruments and Methods in Physics Research Section A2001，，： | 2 |
| 12 | Ziegler-Natta catalysis Adv Organomet显示文摘 | Kaminsky W | 1980 | Chem Rev1980，18，： | 1 |
| 13 | Pathophysiologic basis of contrast enhancement in breast tumor显示文摘 | Knopp NW Weiss E Sinn HP | 1999 | Magn Reson Imaging1999，10，7： | 1 |
| 14 | Living pol- ymers on polymerization with extremely productive Zie- gler catalysts显示文摘 | Sinn H Kaminsky W Vollmer H J | | 0，，05： | 1 |
| 15 | Highly sensitive and selective reversible sensor for the detection of Cr3+显示文摘 | Weerasinghe A J Schmiesing C Sinn E | 2009 | Tetrahedron Letters2009，50，： | 1 |
| 16 | Centrosomal aberrations in primary invasive breast cancer are associated with nodal status and hormone receptor expression显示文摘 | Schneeweiss A Sinn HP Ehcmann V | 2003 | Int J Cancer2003，107，3： | 1 |
| 17 | Differential response of four tree species to ozone-induced acceleration of foliar senescence显示文摘 | Pell E J Sinn J P Brendley B W | 1999 | Plant Cell & Environment1999，22，7： | 1 |
| 18 | Comparison of immunohistochemistry and RT-PCR for detection of CD44-expression:a new prognostic factor in human breast cancer显示文摘 | Dall P Heider KH Sinn HP | 1995 | Int J Cancer1995，60，4： | 1 |
| 19 | Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor,ENMD-2076,against multiple myeloma显示文摘 | WANG X J SINN A L POLLOK K | 2010 | Br J Haematol2010，150，3： | 1 |
| 20 | Saving - Investment Correlations and Capital Mobility : on the Evidence from Annual Data 显示文摘 | Sinn S | 1992 | Eco- nomic Journal1992，102，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员